Johnson &a; Johnson Development Corporation
Johnson &a; Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Business Model: B2C B2B
Revenue: $16.3M
Employees: 2-10
Rankings
Detailed Johnson &a; Johnson Development Corporation Information
Geographic Data
Address: 410 George St
City: New Brunswick
State: NJ
Zip: 08901
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Johnson &a; Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson &a; Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson &a; Johnson. JJDC plays an integral role in the identification of new business opportunities outside of Johnson &a; Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson &a; Johnson operating companies.
Contact Phone:
+17325243214
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2005 | 7TM Pharma | Venture Round | - |
| 6/2012 | PhaseBio Pharmaceuticals | Series B | 23M |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 6/2007 | Aquinox Pharmaceuticals | Series A | 14.5M |
| 5/2007 | CVRx | Series D | 65M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 7/2013 | CVRx | Series F | 0 |
| 2/2012 | Celladon | Venture Round | 43M |
| 11/2009 | Celladon | Series C | 21.8M |
| 12/2012 | Biocartis | Series D | 0 |
| 6/2009 | Pronota | Series B | 7.4M |
| 8/2003 | Biolex Therapeutics | Venture Round | 0 |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 6/2013 | Protagonist Therapeutics | Series B | 0 |
| 6/2013 | Vedanta Biosciences | Venture Round | - |
| 3/2004 | InSound Medical | Series D | 17.2M |
| 11/2001 | Locus Pharmaceuticals | Series C | 0 |
| 11/2000 | Locus Pharmaceuticals | Series B | 0 |
| 3/2011 | Astute Medical | Series B | 13M |
| 11/2010 | 23andMe | Series C | 22.2M |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 8/2008 | Neuron Systems | Series A | 9M |
| 5/2010 | Astute Medical | Series B | 26.5M |
| 5/2010 | Breathe Technologies | Series C | 23M |
| 5/2000 | Global Telemedix | Series B | 0 |
| 3/2006 | 7TM Pharma | Series C | 0 |
| 9/2009 | NovoCure | Venture Round | - |
| 9/2009 | Neotract | Series B | 28.1M |
| 8/2004 | Othera Pharmaceuticals | Series B | 0 |
| 4/2006 | Pronota | Series A | 7.8M |
| 10/2010 | Intio | Series B | 8.1M |
| 5/2012 | Mitralign | Series D | 0 |
| 3/2017 | Grail | Series B | 0 |
| 1/2012 | Pronota | Series C | 4.8M |
| 6/2011 | Spinal Modulation | Series D | 0 |
| 10/2003 | OmniSonics Medical Technologies | Series C | 43M |
| 7/2013 | ViaCyte | Series C | 10.6M |
| 11/2003 | CardioMEMS | Series B | 0 |
| 1/2004 | Animas Corporation | Venture Round | 16.9M |
| 1/2003 | Vascular Architects | Series D | 0 |
| 5/2006 | ViaCyte | Venture Round | 0 |
| 7/2004 | Intrapace | Series C | 0 |
| 3/2003 | Sopherion Therapeutics | Series A | 0 |
| 11/2010 | Syntaxin | Series C | 29M |
| 1/2010 | PhaseBio Pharmaceuticals | Series B | 25M |
| 7/2000 | Lumenos | Series B | 34M |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2005 | Ilypsa | Series B | 36M |
| 12/2000 | InfoMedics | Venture Round | 10M |
| 5/2009 | iScience Interventional | Series F | 20.5M |
| 1/2008 | Arbor Surgical Technologies | Series C | 0 |
| 12/2007 | Mitralign | Series C | 0 |
| 10/2004 | Acuity Pharmaceuticals | Series B | 0 |
| 4/2013 | Aquinox Pharmaceuticals | Series C | 0 |
| 6/2014 | Aduro BioTech | Series C | 55.7M |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 7/2008 | CVRx | Series E | 0 |
| 9/2002 | CellGate | Series D | 10M |
| 6/2003 | Orqis Medical | Series C | 25M |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 3/2004 | BioRexis | Series B | 30M |
| 7/2007 | ViaCyte | Series C | 0 |
| 7/2002 | Transvascular | Series D | 10.8M |
| 1/2011 | Zeo | Series C | 0 |
| 10/2007 | Syntaxin | Series B | 32M |
| 7/2013 | ReVision Optics | Series E | 55M |
| 5/2005 | Mazor Robotics | Series B | 10M |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 12/2000 | Sleep Solutions | Series D | 8M |
| 6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
| 11/2013 | Biocartis | Series E | 0 |
| 5/2014 | Rodin Therapeutics | Series A | 12.9M |
| 6/2013 | Rodin Therapeutics | Seed Round | - |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 6/2009 | CoAxia | Series D | 21.5M |
| 10/2007 | Tengion | Series C | 33M |
| 6/2006 | Tengion | Series B | 50M |
| 7/2013 | NeuroPace | Venture Round | 18M |
| 7/2003 | InSound Medical | Series D | 6.5M |
| 8/2011 | NeuroPace | Venture Round | 0 |
| 1/2015 | Willow | Series A | 15M |
| 6/2000 | iKnowMed | Series C | 30.7M |
| 10/2007 | PhaseBio Pharmaceuticals | Venture Round | 6.6M |
| 10/2005 | Light Sciences Oncology | Series A | 35M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 1/2012 | iScience Interventional | Venture Round | 2.8M |
| 12/2009 | Genocea Biosciences | Series B | 25.7M |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 10/2012 | Genocea Biosciences | Series C | 30M |
| 8/2005 | Tengion | Series A | 39M |
| 7/2011 | Binx Health | Series B | 27.1M |
| 10/2013 | Merus | Series B | 42.2M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 8/2008 | Brainsgate | Series C | 27.5M |
| 1/2011 | Genocea Biosciences | Series B | 35M |
| 3/2009 | GI Dynamics | Series C | 0 |
| 9/2005 | Biolex Therapeutics | Series B | 36M |
| 5/2007 | Biolex Therapeutics | Series C | 30M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 7/2011 | Nevro | Series B | 58M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 3/2013 | Nevro | Series C | 0 |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 8/2007 | Molecular Partners | Series A | 15.6M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 12/2009 | Molecular Partners | Series B | 44.2M |
| 1/2014 | TopiVert | Venture Round | 7.4M |
| 4/2014 | Binx Health | Series B | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 93M |
| 11/2004 | Corthera | Series B | 15M |
| 5/2014 | Inspire Medical Systems | Series E | 0 |
| 7/2004 | Accumetrics | Series B | 0 |
| 7/2003 | Immunicon | Series F | 24.8M |
| 11/2014 | La Lumiere | Series B | 20M |
| 3/2007 | Orqis Medical | Series D | 12M |
| 3/2009 | GetWellNetwork | Series C | 10M |
| 3/2007 | Axial Biotech | Series B | 15.3M |
| 1/2014 | PowerVision | Series D | 0 |
| 12/2005 | Light Sciences Oncology | Series A | 32M |
| 3/2000 | Cyrano Sciences | Venture Round | 23M |
| 4/2013 | ReVision Optics | Equity | 15M |
| 11/2011 | Biocartis | Series C | 95.8M |
| 3/2000 | InfoMedics | Venture Round | 6M |
| 4/2001 | Vascular Architects | Series C | 20M |
| 11/2009 | Spinal Modulation | Series C | 27.4M |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 9/2014 | Inivata | Venture Round | 6.6M |
| 2/2008 | InSound Medical | Series E | 11M |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 10/2007 | Optherion | Series A | 37M |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 7/2006 | InSound Medical | Series E | 18.9M |
| 11/2013 | Pulmocide | Series A | 27.6M |
| 8/2009 | Neurosearch | Venture Round | 14.3M |
| 1/2002 | Sleep Solutions | Series E | 7M |
| 10/2009 | Sleep Solutions | Series F | 20M |
| 10/2003 | Sleep Solutions | Venture Round | 6.1M |
| 5/2000 | Sleep Solutions | Series C | 3M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 6/2010 | Aquinox Pharmaceuticals | Series B | 0 |
| 2/2013 | OptiScan Biomedical | Private Equity Round | 30.7M |
| 2/2009 | ImaCor | Series A | 0 |
| 9/2012 | Catalyst Biosciences | Post-IPO Equity | 13.4M |
| 2/2016 | Cala Health | Series B | 0 |
| 4/2010 | Biocartis | Series B | 40M |
| 4/2002 | Replidyne | Series A | 13M |
| 9/2014 | Biocartis | Series F | 0 |
| 12/2014 | Padlock Therapeutics | Series A | 23M |
| 6/2001 | NitroMed | Series E | 0 |
| 1/2011 | 23andMe | Series C | 9M |
| 1/2012 | PowerVision | Series C | 12.5M |
| 1/2005 | Biolex Therapeutics | Venture Round | 8M |
| 9/2002 | KuDOS Pharmaceuticals Ltd | Series C | 45.2M |
| 10/2008 | Biolex Therapeutics | Series D | 0 |
| 5/2002 | eNeura Therapeutics | Series A | 1M |
| 9/2004 | Vascular Architects | Series E | 0 |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 0 |
| 3/2017 | Grail | Series B | 0 |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 11/2016 | ReVision Optics | Venture Round | 0 |
| 2/2016 | Cala Health | Series B | 0 |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 1/2015 | Willow | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
